1,2-bis(3,5-dioxopiperazin-1-yl)ethane has been researched along with bimolane in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Creighton, AM; el-Hage, AN; Ferrans, VJ; Herman, EH; Witiak, DT | 1 |
| Camerman, A; Camerman, N; Hempel, A | 1 |
| Guo, Y; Xie, X; Xue, Y | 1 |
| Lu, DY; Lu, TR | 1 |
| Eastmond, DA; Hasegawa, LS; Vuong, MC | 1 |
1 review(s) available for 1,2-bis(3,5-dioxopiperazin-1-yl)ethane and bimolane
| Article | Year |
|---|---|
Antimetastatic activities and mechanisms of bisdioxopiperazine compounds.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Transformed; Fibrinogen; Humans; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Piperazines; Razoxane | 2010 |
4 other study(ies) available for 1,2-bis(3,5-dioxopiperazin-1-yl)ethane and bimolane
| Article | Year |
|---|---|
Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters.
Topics: Animals; Body Weight; Cricetinae; Daunorubicin; Male; Mesocricetus; Piperazines; Razoxane; Stereoisomerism; Structure-Activity Relationship | 1985 |
Bimolane: structure determination indicates anticancer activity is attributable to ICRF-154.
Topics: Antineoplastic Agents; Models, Molecular; Piperazines; Razoxane; X-Ray Diffraction | 1984 |
Translocation t(7;11)(P15;P15) in a patient with therapy-related acute myeloid leukemia following bimolane and ICRF-154 treatment for psoriasis.
Topics: Acute Disease; Adult; Antineoplastic Agents; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 7; Humans; Karyotyping; Leukemia, Myeloid; Male; Neoplasms, Second Primary; Psoriasis; Razoxane; Translocation, Genetic | 1997 |
A comparative study of the cytotoxic and genotoxic effects of ICRF-154 and bimolane, two catalytic inhibitors of topoisomerase II.
Topics: Antineoplastic Agents; Cell Line; Cell Survival; Chromosome Aberrations; Cytokinesis; Humans; Lymphocytes; Micronucleus Tests; Mutagenicity Tests; Mutagens; Razoxane; Topoisomerase II Inhibitors | 2013 |